Head growth in infants with infantile spasms may be temporarily reduced

Zvonka Rener-Primec1, Jana Lozar-Krivec, Uros Krivec

  • 1Department of Child, Adolescent and Developmental Neurology, University Children's Hospital, Ljubljana, Slovenia. zvonka.rener@mf.uni-lj.si

Pediatric Neurology
|August 31, 2006
PubMed

Insights

Infants with infantile spasms may experience temporary head growth reduction. Head circumference below the tenth percentile predicts later mental retardation in these children.

Area of Science:

  • Pediatric Neurology
  • Developmental Neuroscience

Background:

  • Epileptic activity, a feature of epileptic encephalopathies, can impede brain development.
  • Infantile spasms (IS) represent a specific epileptic syndrome affecting infants.
  • The impact of IS on head growth rates has not been previously investigated.

Purpose of the Study:

  • To investigate the rate of head growth in infants diagnosed with infantile spasms.
  • To determine if head circumference measurements can predict mental outcomes in infants with IS.

Main Methods:

  • A retrospective study involving 38 infants with infantile spasms.
  • Analysis of head circumference measurements during the period of spasms.
  • Assessment of mental outcomes at follow-up.

Main Results:

  • While mean head circumference was not significantly smaller than normal, a higher proportion (27%) of infants with IS had head circumference below the tenth percentile.
  • Head circumference below the tenth percentile at 4-5 months post-IS onset significantly correlated with later mental retardation (P = 0.004).
  • No correlation was found between specific IS treatments and head circumference outcomes.

Conclusions:

  • Transiently diminished head growth in infants with IS temporally aligns with spasm onset and can recover during remission.
  • Epileptic activity during sensitive developmental periods may negatively influence brain growth.
  • Head circumference serves as a reliable predictor of mental outcomes in children with infantile spasms.

Related Concept Videos

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Tetanus01:29

Tetanus

Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...